Aurobindo Pharma's wholly owned step-down subsidiary, PT Aurogen Pharma Indonesia, has incorporated a new entity named PT Auro Pharm Indonesia to undertake manufacturing operations in Indonesia. The new subsidiary was incorporated on July 1, 2026, with regulatory approval received on July 9, 2026. The incorporation is part of the company's strategy to expand its manufacturing footprint in the pharmaceutical sector.

The disclosure regarding this incorporation was made to the National Stock Exchange of India Limited and BSE Limited on July 10, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirmed that PT Auro Pharm Indonesia is a wholly owned step-down subsidiary and falls under the definition of a related party transaction. The promoters and promoter group of Aurobindo Pharma have no interest in this transaction.

The initial subscription to the share capital of PT Auro Pharm Indonesia was made entirely in cash. The total capital subscribed amounts to IDR 20,000,000,000, divided into 2000 equity shares with a face value of IDR 10,000,000 each. Aurobindo Pharma holds 100% of the shareholding and control in the newly incorporated entity.

Key Details of PT Auro Pharm Indonesia

No specific governmental or regulatory approvals were required for this acquisition beyond the standard incorporation process. As a newly formed entity, PT Auro Pharm Indonesia does not have a historical turnover record for the past three years. The primary object of the subsidiary is to engage in manufacturing operations, aligning with Aurobindo Pharma's core business activities.

Citi has reiterated its Sell recommendation on aurobindo pharma , raising the target price to ₹1,270 from ₹1,020, even as the brokerage acknowledges the stock's recent strong rally. The upward revision in the target price reflects the broader market re-rating, but the maintained Sell stance signals that Citi views the current valuation as unsustainable relative to fundamental growth prospects.

Valuation Concerns Drive Cautious Outlook

Citi's primary concern centers on stretched valuations, with the recent rally having pushed the stock to 2 standard deviations above its historical averages. According to the brokerage, the current market price already prices in potential benefits from foreign exchange tailwinds and the Production Linked Incentive (PLI) scheme, leaving little room for further upside. The stock is trading at 20x FY28E EPS, a multiple that Citi considers elevated given the company's growth trajectory.

The key valuation and rating parameters as highlighted by Citi are summarised below:

Growth Headwinds in FY28–29

Beyond near-term valuation concerns, Citi flags a set of structural challenges that are expected to weigh on Aurobindo Pharma's growth momentum in FY28–29. The brokerage points to limited pipeline visibility as a key risk, suggesting that the company may face difficulty sustaining its current earnings trajectory beyond the near term. Additionally, weaker prospects for Lannett — Aurobindo Pharma's US-based subsidiary — are cited as a drag on the overall growth outlook.

The following factors underpin Citi's cautious view on the company's medium-to-long-term growth:

• Limited pipeline visibility constraining future revenue growth
• Weaker Lannett prospects impacting the US business segment
• Modest long-term PAT CAGR limiting earnings expansion
• Stretched valuations at 20x FY28E EPS offering limited margin of safety
• FX and PLI benefits already priced in at current market levels

Brokerage Stance

While the revised target price of ₹1,270 represents an upward adjustment from the earlier target of ₹1,020, Citi's Sell rating reflects the view that the stock's risk-reward remains unfavourable at current levels. The combination of elevated valuations, slowing growth visibility, and sector-specific headwinds forms the basis of the brokerage's continued cautious stance on Aurobindo Pharma.